184
Views
16
CrossRef citations to date
0
Altmetric
Reports

Topical photodynamic therapy with 5-aminolevulinic acid in Chinese patients with Rosacea

, , , , &
Pages 196-200 | Received 04 May 2018, Accepted 11 Jul 2018, Published online: 24 Jul 2018
 

ABSTRACT

Background: Rosacea is difficult to cure and frequently recurs. Topical photodynamic therapy (PDT) has been tentatively used, with only preliminary results reported.

Objective: To evaluate the efficacy and safety of topical PDT in Chinese patients with rosacea.

Methods & Materials: Seventeen participants with rosacea were treated three times using 5-aminolevulinic acid (ALA)-PDT at intervals of 7–10 days. Papule and pustule numbers, erythema severity, telangiectasia severity, physician’s global assessment (PGA) score (1 [best]–6), and patient satisfaction score (0–3 [highest]) were assessed. Rosacea improvement and the total effective rate were calculated. Stratum corneum hydration and sebum levels, and the melanin index (MI) and erythema index (EI) were measured non-invasively.

Results: After three treatments with ALA-PDT, the total effective rate (≥50% improvement) was 64.71%, mean PGA score was 2.88 ± 0.93, and mean patient satisfaction score was 1.71 ± 0.69. The EI significantly decreased 1 month after the final treatment (from 468 ± 80.61 to 439 ± 77.78 for the forehead and from 507.65 ± 92.51 to 483.27 ± 78.32 for the nasal ala). Four participants received three additional treatments. They achieved 50–74% improvement after three treatments and ≥75% improvement after six treatments.

Conclusion: ALA-PDT is safe and effective for treating rosacea.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The study was supported by Liaoning Provincial Natural Science Fund (Code 201602837)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.